Strontium-89 therapy for the treatment of huge osseous metastases in prostate carcinoma: A case report

Zhang,Wenjie; Zhao,Weiwei; Jia,Zhiyun; Deng,Houfu

doi:10.3892/etm.2012.807

Strontium-89 therapy for the treatment of huge osseous metastases in prostate carcinoma: A case report

Authors:
- Wenjie Zhang
- Weiwei Zhao
- Zhiyun Jia
- Houfu Deng
View Affiliations

Affiliations: Department of Nuclear Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: November 12, 2012 https://doi.org/10.3892/etm.2012.807
Pages: 608-610

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Prostate cancer is a growing public health problem. The palliation of pain in patients with painful bone metastases is of primary importance in the clinical management of advanced cancer. Internal therapy with radionuclides, which concentrate at sites of increased bone turnover, is used to control pain and improve quality of life as an alternative to conventional therapies. In the present study, we report the case of a 52-year‑old male who had been diagnosed with prostate cancer. The patient presented with severe pain in multiple areas, but particularly in the right hip. A whole-body bone scan revealed that the right hip, ilium and ischium were covered with huge metastatic lesions. Treatment with radionuclide strontium-89 chloride (89Sr) resulted in a partial response which was confirmed by the successful relief of pain and other imaging modalities. No significant change in the leukocyte or thrombocyte levels was observed. The results of the present study indicate that systemic radionuclide therapy using 89Sr is an effective, well-tolerated and safe palliative treatment in patients with huge osseous metastases in prostate carcinoma.

View Figures

View References

1.	Heidenreich A, Aus G, Bolla M, et al: EAU guidelines on prostate cancer. Eur Urol. 53:68–80. 2008. View Article : Google Scholar : PubMed/NCBI
2.	Jacobs SC: Spread of prostatic cancer to bone. Urology. 21:337–344. 1983. View Article : Google Scholar : PubMed/NCBI
3.	Morris MJ and Scher HI: Clinical approaches to osseous metastases in prostate cancer. Oncologist. 8:161–173. 2003. View Article : Google Scholar : PubMed/NCBI
4.	Hillegonds DJ, Franklin S, Shelton DK, Vijayakumar S and Vijayakumar V: The management of painful bone metastases with an emphasis on radionuclide therapy. J Natl Med Assoc. 99:785–794. 2007.PubMed/NCBI
5.	Finlay IG, Mason MD and Shelley M: Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol. 6:392–400. 2005. View Article : Google Scholar : PubMed/NCBI
6.	Blake GM, Zivanovic MA, McEwan AJ and Ackery DM: Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med. 12:447–454. 1986. View Article : Google Scholar : PubMed/NCBI
7.	Giammarile F, Mognetti T and Resche I: Bone pain palliation with strontium-89 in cancer patients with bone metastases. Q J Nucl Med. 45:78–83. 2001.PubMed/NCBI
8.	Robinson RG: Strontium-89-precursor targeted therapy for pain relief of blastic metastatic disease. Cancer. 72(Suppl S11): 3433–3435. 1993. View Article : Google Scholar : PubMed/NCBI
9.	Dearnaley DP, Bayly RJ, A'Hern RP, Gadd J, Zivanovic MM and Lewington VJ: Palliation of bone metastases in prostate cancer. Hemibody irradiation or strontium-89? Clin Oncol (R Coll Radiol). 4:101–107. 1992. View Article : Google Scholar : PubMed/NCBI
10.	Mercadante S and Fulfaro F: Management of painful bone metastases. Curr Opin Oncol. 19:308–314. 2007. View Article : Google Scholar
11.	McQuay HJ, Collins SL, Carroll D and Moore RA: Radiotherapy for the palliation of painful bone metastases (Review). Cochrane Database Syst Rev. CD0017932000.
12.	Di Lorenzo G, Autorino R, Ciardiello F, et al: External beam radiotherapy in bone metastatic prostate cancer: impact on patients' pain relief and quality of life. Oncol Rep. 10:399–404. 2003.
13.	Polascik TJ: Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases. Drug Des Devel Ther. 3:27–40. 2009.PubMed/NCBI
14.	Major P: Optimal management of metastatic bone disease. Eur J Oncol Nurs. 11(Suppl 2): S32–S37. 2007. View Article : Google Scholar
15.	Nightengale B, Brune M, Blizzard SP, Ashley-Johnson M and Slan S: Strontium chloride Sr 89 for treating pain from metastatic bone disease. Am J Health Syst Pharm. 52:2189–2195. 1995.PubMed/NCBI
16.	Bauman G, Charette M, Reid R and Sathya J: Radiopharmaceuticals for the palliation of painful bone metastasis-a systemic review. Radiother Oncol. 75:258–270. 2005. View Article : Google Scholar : PubMed/NCBI
17.	Li WB, Höllriegl V, Roth P and Oeh U: Influence of human biokinetics of strontium on internal ingestion dose of ⁹⁰Sr and absorbed dose of ⁸⁹Sr to organs and metastases. Radiat Environ Biophys. 47:225–239. 2008. View Article : Google Scholar : PubMed/NCBI
18.	Ben-Josef E, Maughan RL, Vasan S and Porter AT: A direct measurement of strontium-89 activity in bone metastases. Nucl Med Commun. 16:452–456. 1995. View Article : Google Scholar : PubMed/NCBI